Détails Publication
Epidemiological, Diagnostic and Evolutionary Profile of Stomach Cancer at Bogodogo University Hospital (Chub) in Ouagadougou (Burkina Faso),
Discipline: Médecine clinique
Auteur(s): Bambara Hierrhum Aboubacar, Zerbo Nina Assanatou Jumelle, Kouraogo SoniaYasmina, Coulibaly Aboubacar, ZIDA Maurice
Renseignée par : BAMBARA Hierrhum Aboubacar
Résumé

Introduction: According to WHO estimates, in 2020 there will be over 1.1 million cases of stomach cancer,
including 770,000 deaths, and it remains the third leading cause of cancer deaths worldwide. In Burkina Faso, Zoungrana et al. (2021) noted that stomach cancer ranked second among digestive cancers, with a prevalence of 74.28%. The aim of our study was to determine the epidemiological, diagnostic and evolutionary profile of stomach cancer in Ouagadougou. Patients and methods: This was a retrospective and descriptive study carried out in the Oncology and Clinical Hematology Department of CHUB in Ouagadougou from January 1, 2018 to December 31, 2022. We included in our study all patients who presented a stomach cancer confirmed by anatomo-pathological examination and who consulted in oncology and/or were hospitalized during the study period. Results: During the study period, 50 cases of gastric cancer were diagnosed, representing a hospital prevalence of 9.15%. The mean age of our patients was 57.6 years. The female gender was predominant (58% female). The most important risk factor was the consumption of salty foods (98%). Epigastric pain was the most frequent warning sign, found in 98% of patients, followed by vomiting (88%). Endoscopically, antral location was the most frequent with 58%. Adenocarcinoma was the most frequent histological appearance with 88%. The ulcerative-bourgeous aspect was the most frequent in 82% of patients. 66% of patients had secondary locations. The liver was the most frequent site of metastasis in 58% of patients. We found 66% of patients with stage IV pathology. In our study, 58% of patients received treatment, of which 83% of patients received palliative
treatment. Surgical treatment was performed in 30%, partial gastrectomy in 80% of patients. In our study, 58% of patients received chemotherapy. The Folfox protocol was more used with 79.31%. At the end of our study, 32% of our patients were alive. The median survival was 2 months. Conclusion: Stomach cancer is not very common in our context. The implementation of awareness programs for the population is necessary.

Mots-clés

Stomach, Cancer

935
Enseignants
5615
Publications
49
Laboratoires
84
Projets